SEOUL, Korea (Nov. 3, 2015) — Amgen, one of the world’s leading biotechnology companies, announced a new affiliate opening in Korea to bring high-quality, innovative therapies for grievous illnesses.
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering human therapeutics, and is focused on delivering its robust, late-stage pipeline of potential new medicines to patients around the world. Amgen’s entry into Korea is expected to bring more clinical trials and new treatments for grievous illness to patients in Korea. For Amgen, it is an important step in the Company’s global expansion efforts.
Amgen’s initial priorities in Korea will include:
Amgen has initiated multiple drug registrations in Korea; pending approval by the MFDS, Amgen plans to make these medicines available to patients in Korea as soon as possible.
The Company recently appointed Sang Noh as the General Manager of Amgen Korea. Noh has been in the pharmaceutical industry since 1987 and has demonstrated expertise in developing and implementing market strategies. Prior to joining Amgen, he was the Country Division Head for Bayer Healthcare in Korea.
Noh commented that “Amgen is delighted to be establishing an affiliate in Korea, where biotechnology is one the fastest growing industries in Korea,” and Noh added that, “As a biotechnology pioneer, Amgen will be committed to expanding treatment options for both patients and healthcare providers while striving to serve patients by developing and delivering innovative therapeutics.”
For the past five years, Amgen Korea has invested 25 billion KRW for its clinical trials and 29 clinical trials have been conducted, of which 18 studies are currently ongoing, with more than 1,200 enrolled subjects across 171 clinical trial sites. A worldwide leader in biologics manufacturing, Amgen has an outstanding track record of delivering high-quality medicines to patients who need them. The Company is headquartered in Thousand Oaks, Calif. and has operations in more than 75 markets around the world, including Japan, China and Korea.
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.
Amgen focuses on areas of high unmet medical need and leverages its biologics manufacturing expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.
For more information, visit www.amgen.com
Forward Looking Statements
This news release contains forward-looking statements that involve significant risks and uncertainties, including those discussed below and others that can be found in our Form 10-K for the year ended Dec. 31, 2014, and in any subsequent periodic reports on Form 10-Q and Form 8-K. Amgen is providing this information as of the date of this news release and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.
No forward-looking statement can be guaranteed and actual results may differ materially from those we project. The Company's results may be affected by our ability to successfully market both new and existing products domestically and internationally, clinical and regulatory developments (domestic or foreign) involving current and future products, sales growth of recently launched products, competition from other products (domestic or foreign), and difficulties or delays in manufacturing our products. In addition, sales of our products are affected by reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment as well as U.S. legislation affecting pharmaceutical pricing and reimbursement. Government and others' regulations and reimbursement policies may affect the development, usage and pricing of our products. Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. We or others could identify safety, side effects or manufacturing problems with our products after they are on the market. Our business may be impacted by government investigations, litigation and product liability claims. If we fail to meet the compliance obligations in the corporate integrity agreement between us and the U.S. government, we could become subject to significant sanctions. Further, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors. We depend on third parties for a significant portion of our manufacturing capacity for the supply of certain of our current and future products and limits on supply may constrain sales of certain of our current products and product candidate development. In addition, we compete with other companies with respect to some of our marketed products as well as for the discovery and development of new products. Discovery or identification of new product candidates cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate will be successful and become a commercial product. Further, some raw materials, medical devices and component parts for our products are supplied by sole third-party suppliers. Our business performance could affect or limit the ability of our Board of Directors to declare a dividend or our ability to pay a dividend or repurchase our common stock.
# # #
CONTACT: Edelman Korea, Seoul
Jane Park, Senior supervisor (82) 10-9307-7188 (mobile) or (82) 2-2022-8203 (office)
Binnali Do, Supervisor (82) 10-7773-1794 (mobile) or (82) 2-2022-8226 (office)
Lena Han, Account executive (82) 10-9409-4231 (mobile) or (82) 2-2022-8273 (office)